about
Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanismsDendritic cells express multiple chemokine receptors used as coreceptors for HIV entryBuilding from the HIV Response toward Universal Health Coverage.Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention.The United States President's Emergency Plan for AIDS Relief: a story of partnerships and smart investments to turn the tide of the global AIDS pandemic.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.HIV preferentially infects HIV-specific CD4+ T cells.Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma.Structured Treatment Interruption: Approaches and Risks.Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.AIDS: lessons learnt and myths dispelled.An assessment of interactions between global health initiatives and country health systems.Lessons learned from PEPFAR.Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis.Developing an evidence-based, preventive care package for persons with HIV in Africa.Defeating AIDS--advancing global health.Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy.Ending cervical cancer: A call to action.The role of dendritic cells in the infection of CD4+ T cells with the human immunodeficiency virus: use of dendritic cells from individuals homozygous for the delta32CCR5 allele as a model.A healthy perspective: the post-2015 development agenda.Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor.Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings.Phylodynamic analysis to inform prevention efforts in mixed HIV epidemics.MDG 6 and beyond: from halting and reversing AIDS to ending the epidemic.Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study.The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.Promethean thymus?Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.Neglected tropical diseases and HIV/AIDS.[HIV/AIDS, tuberculosis and malaria can now be effectively combated].Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.A grand convergence and a historic opportunity.
P50
Q22009094-52B23251-60BF-4BB1-9698-04C247DDD107Q24309573-EC8FE64E-7E56-41A3-AEC8-548D199B76E6Q26694535-BB59116E-0B3F-4076-B2B2-0C4450281D72Q30361444-76D01317-492C-45E1-8513-81B32E17C966Q30419198-FADDFFED-A1C8-432A-91AC-FE26620BD64EQ33952995-92049BB8-095A-4CBD-B76F-7543D62EDC62Q33958893-B2AA2926-7ACF-4138-9008-E1C8E53D39BCQ33964717-3B65C341-4877-439E-8B58-410E077D176EQ34344167-F9B8996A-DC0F-4CDE-BC4D-FFE3BD9B24DDQ34583760-34621E55-32C6-446D-8AD0-F89EE0B99701Q34593086-0D7EC1B2-5158-4CF2-B460-4C60BED75CB0Q34755325-3D4B20BF-2FD3-40C8-84FB-58F01563740DQ36474240-7108BD6D-01DE-4846-AD0D-E25D3DB758EEQ36488962-CD630E57-9BE4-449F-888C-1BCCEFEAD1A1Q36783609-C3241F57-983E-478E-9BD5-5DCA8399E88FQ37359827-B3E49C6F-12F4-42EB-A673-BE70CA89B98AQ37419855-9CFB3F41-4E6B-405F-BF84-04E21B4706B4Q37525469-C59784BF-2F58-4759-ACF0-9B002A0328C9Q37621965-CC5DCB1D-0BB0-4577-9CCA-EF7DF967FC99Q37773746-9A58F53B-387A-4415-9E42-3861B760A4A1Q38040627-2E47D649-3C61-4AEB-B705-2563ECF55424Q38456034-36130306-92F7-4118-9AAD-0165C75C0853Q38539190-16314440-1DEE-4207-AAA9-329860520486Q38869763-21E77FA7-AC53-4F98-99B3-8294B42125FCQ38871168-07CEB634-110A-47C3-BE0B-9FCEAD8C444FQ38878266-1E8D4F81-057D-4D41-AD9A-E6BDE9D6515AQ38980696-4610197D-630B-4A2D-BB80-9369E69E428DQ39442835-11581441-935E-4937-BF9D-CDFE2B0C90B4Q39585768-DE36F31A-24C9-4CCD-9614-BD30C9B58F16Q39606566-8A60545A-A8DA-4C8E-8674-1A92EFCEAAFCQ40095216-2AF1AEA6-6E8C-4FD6-8DCD-62B625559CB8Q42204017-D909523A-A6F5-4AAF-8833-9E69F858399EQ42205359-58A16EFE-9DEB-4E1A-A3B7-2D3967ED111DQ42279773-559CD0B0-8C7D-4153-9996-33E0FED27F34Q42363024-9C4D1A4F-C7AE-410A-8E5C-5CE514E422C7Q43833986-F28DE531-CE2A-416A-A10B-1F524BE42201Q43840231-DAC4EC6F-F80D-43A1-96EB-44EA52471C9CQ44368644-EB05BEC7-C7B0-4313-A60B-97EDE71370E7Q44517872-B8394FFD-B353-499D-B76A-355247D402BEQ44640357-CBA5B805-A088-46B3-A6F8-C59E50AFF9A9
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Mark Dybul
@ast
Mark Dybul
@en
Mark Dybul
@es
Mark Dybul
@nl
Mark Dybul
@sl
type
label
Mark Dybul
@ast
Mark Dybul
@en
Mark Dybul
@es
Mark Dybul
@nl
Mark Dybul
@sl
prefLabel
Mark Dybul
@ast
Mark Dybul
@en
Mark Dybul
@es
Mark Dybul
@nl
Mark Dybul
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0002-3609-4526
P735
P7859
viaf-285089745